BioCryst Pharmaceuticals
BCRX • NASDAQ
BioCryst Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Charles K. Gayer, with a market cap of $2.3B.
CEOCharles K. Gayer
Next Earnings
Upcoming earnings announcement for BioCryst Pharmaceuticals
Date
Monday, May 4, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.09
Revenue Estimate
$154.5M
Earnings History
Past 12 earnings reports for BioCryst Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | $0.06Est: $0.07 | -21.4% | $163.3MEst: $150.5M | +8.5% |  10-K |
| Nov 3, 2025 | Q3 2025 | $0.16Est: $0.08 | +100.0% | $159.4MEst: $162.2M | -1.8% | 10-Q |
| Aug 4, 2025 | Q2 2025 | $0.15Est: $0.03 | +400.0% | $163.4MEst: $149.4M | +9.3% | 10-Q |
| May 5, 2025 | Q1 2025 | $0.00Est: -$0.05 | +100.0% | $145.5MEst: $127.8M | +13.9% | 10-Q |
| Feb 24, 2025 | Q4 2024 | -$0.13Est: -$0.06 | -116.7% | $131.5MEst: $130.1M | +1.1% | 10-K |
| Nov 4, 2024 | Q3 2024 | -$0.07Est: -$0.06 | -16.7% | $117.1MEst: $112.5M | +4.1% | 10-Q |
| Aug 5, 2024 | Q2 2024 | -$0.06Est: -$0.17 | +64.7% | $109.3MEst: $98.5M | +11.0% | 10-Q |
| May 6, 2024 | Q1 2024 | -$0.17Est: -$0.21 | +19.0% | $92.8MEst: $85.6M | +8.4% | 10-Q |
| Feb 26, 2024 | Q4 2023 | -$0.28Est: -$0.24 | -16.7% | $93.4MEst: $90.0M | +3.8% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.19Est: -$0.23 | +17.4% | $86.7MEst: $86.0M | +0.9% | — |
| Aug 3, 2023 | Q2 2023 | -$0.24Est: -$0.25 | +4.0% | $82.5MEst: $82.0M | +0.6% | 10-Q |
| May 3, 2023 | Q1 2023 | -$0.28Est: -$0.30 | +6.7% | $68.8MEst: $71.7M | -4.0% | — |